An Open-Label, Randomized, Multi-Center, Phase III Study to Compare the Safety and Efficacy of TKI258 vs Sorafenib in Patients with Metastatic Renal Cell Carcinoma after Failure on Anti-Angiogenic (VEGFtargeted and mTOR inhibitor) Therapies
|Effective start/end date||8/1/11 → 8/30/15|
- Novartis Pharma AG
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.